GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (OTCPK:SBMFF) » Definitions » Cost of Goods Sold

SBMFF (Sino Biopharmaceutical) Cost of Goods Sold : $734 Mil (TTM As of Dec. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Sino Biopharmaceutical Cost of Goods Sold?

Sino Biopharmaceutical's cost of goods sold for the six months ended in Dec. 2024 was $342 Mil. Its cost of goods sold for the trailing twelve months (TTM) ended in Dec. 2024 was $734 Mil.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Sino Biopharmaceutical's Gross Margin % for the six months ended in Dec. 2024 was 80.82%.

Cost of Goods Sold is also directly linked to Inventory Turnover. Sino Biopharmaceutical's Inventory Turnover for the six months ended in Dec. 2024 was 1.18.


Sino Biopharmaceutical Cost of Goods Sold Historical Data

The historical data trend for Sino Biopharmaceutical's Cost of Goods Sold can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical Cost of Goods Sold Chart

Sino Biopharmaceutical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cost of Goods Sold
Get a 7-Day Free Trial Premium Member Only Premium Member Only 792.49 837.16 643.69 698.84 732.93

Sino Biopharmaceutical Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Cost of Goods Sold Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 219.17 363.02 334.74 392.13 342.20

Sino Biopharmaceutical Cost of Goods Sold Calculation

Cost of Goods Sold is the aggregate cost of goods produced and sold, and services rendered during the reporting period. It excludes Total Operating Expense, such as Depreciation, Depletion and Amortization and Selling, General, & Admin. Expense.

Cost of Goods Sold for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $734 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sino Biopharmaceutical  (OTCPK:SBMFF) Cost of Goods Sold Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Sino Biopharmaceutical's Gross Margin % for the six months ended in Dec. 2024 is calculated as:

Gross Margin %=(Revenue - Cost of Goods Sold) / Revenue
=(1784.41 - 342.197) / 1784.41
=80.82 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Cost of Goods Sold is also directly linked to another concept called Inventory Turnover:

Sino Biopharmaceutical's Inventory Turnover for the six months ended in Dec. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher inventory turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate inventory turnover. An average inventory is a better indication.


Sino Biopharmaceutical Cost of Goods Sold Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's Cost of Goods Sold provided by GuruFocus.com. Please click on the following links to see related term pages.


Sino Biopharmaceutical Business Description

Traded in Other Exchanges
Address
1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG
Listed on the Hong Kong Stock Exchange in 2000, Sino Biopharmaceutical is one of the largest Chinese drugmakers. It started with generic drug manufacturing. Since 2018, Sino Biopharm has been actively pivoting into an innovative drugmaker after the Chinese government launched its volume-based procurement policy for the healthcare industry. As of 2024, 41.8% of the firm's total revenue comes from its innovative product category, which includes innovative drugs and biosimilar drugs. Sino Biopharm's biggest revenue segment is oncology medicines, accounting for 37.2% of total revenue, followed by hepatitis, surgery/analgesia, respiratory, and cardio-cerebral vascular therapeutic areas.

Sino Biopharmaceutical Headlines

From GuruFocus

Matthews China Fund Comments on Sino Biopharmaceutical

By Sydnee Gatewood Sydnee Gatewood 10-25-2019

Sino Biopharmaceutical Ltd's Dividend Analysis

By GuruFocus Research 06-11-2024

Value Idea Contest: Sino Biopharmaceutical

By Matthew Sipos Matthew Sipos 01-10-2019

Matthews China Fund 3rd Quarter Commentary

By Holly LaFon Holly LaFon 10-19-2017

Matthews China Fund Comments on Sino Biopharmaceutical

By Sydnee Gatewood Sydnee Gatewood 01-28-2020

Matthews China Fund Comments on Sino Biopharmaceutical

By Vera Yuan Vera Yuan 10-20-2014

GuruFocus Value Idea Contest Sees 2 Winners!

By Holly LaFon Holly LaFon 07-12-2019